Previous 10 | Next 10 |
Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips People in the U.S. are preparing for a busy Memorial Day Weekend. That includes plenty of travel plans to visit family and friends. However, they’re first going to want to check the latest gas price predictions....
Iovance Biotherapeutics (NASDAQ:IOVA) has lost more than half of its market capitalization the morning hours Friday following a post market selloff Stifel described as an overreaction to the company’s trial data for lead candidate lifileucel in melanoma. The C-144-01 study involved pat...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Iovance Therapeutics (NASDAQ: IOVA ) stock is dropping on melanoma treatment trial results. That’s despite the company planning to move forward with a Biologics License Application (BLA). Investors don...
Gainers: Avadel Pharmaceuticals AVDL +61%. PMV Pharmaceuticals PMVP +25%. Alpha Tau Medical (DRTS) +18%. SIGA Technologies SIGA +18%. Allarity Therapeutics (ALLR) +17%. Losers: Iovance Biotherapeutics (IOVA) -54%. SpringWorks Therapeutics SWTX...
Iovance Biotherapeutics (NASDAQ:IOVA) is trading sharply lower in the post-market Thursday after the clinical-stage biotech indicated a 29% objective response rate (ORR) for the company’s lead candidate C-144-01 in melanoma. The patients in the trial had cancer despite the prior treatm...
Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study Biologics License Application (BLA) Submission Planned for August 2022 Conference Call and Webcast Today at 5:00 p.m. ET SAN CARLOS, ...
Seagen is a phenomenal innovation success story that delivers hope to patients afflicted by deadly cancers while also rewarding shareholders. The approved therapeutics should generate at least $1.6B in revenue this year. Due to various ongoing label expansions, you can expect a much s...
Though there are many companies to choose from, I focus on leading innovators with either novel therapeutics or technologies. NovoCure is a premier developer of tumor treating fields that already enjoyed early market success for glioblastoma multiforme and mesothelioma. As the fir...
The following slide deck was published by Iovance Biotherapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Iovance Biotherapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...